Drug Profile


Alternative Names: BI-Sifrol; Daquiran; Mirapex; Mirapex ER; Mirapex LA; Mirapexin; Pexola; Pramipexole extended-release - Boehringer Ingelheim; Sifrol; Sirfrol ER; SND 919; SND 919Y

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiparkinsonians; Benzothiazoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome
  • No development reported Myoclonus
  • Discontinued Fibromyalgia; Gilles de la Tourette's syndrome; Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myoclonus in USA (PO)
  • 15 Mar 2016 Biomarkers information updated
  • 11 Jan 2012 Boehringer Ingelheim completes a phase III trial in Parkinson's disease in China (NCT01191944)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top